IP Library Granted Patent US 7,405,238
Granted Patent B2
US 7,405,238 · App. 10/235,076 · Granted Jul 29, 2008

Pharmacological inducement of the fed mode for enhanced drug administration to the stomach

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,405,238
App. No.
10/235,076
Granted
Jul 29, 2008
Kind
B2
Abstract

Drugs intended for absorption in the stomach or upper intestinal tract are administered in oral drug delivery systems in conjunction with any of various substances that have been discovered to function as potent agents for inducing the fed mode. By inducing the onset of the fed mode, these agents cause the stomach to prolong its retention of the drug delivery system, which is either large enough to be retained in the stomach during the fed mode or swells or expands to such a size upon ingestion. The fed mode inducing agents include the following compounds and their salts: glycine and glycylglycine, xylitol and related sugar alcohols, sodium and other metal docusates, β-casomorphins, α-lipoic acid and similarly structured acids, 2,2-diaryl-4-(4′-aryl-4′-hydroxypipendino)butyramides, arginine, Trp-Trp, alkylpyridinium halides, dihydroxybenzoic acids, and potent sweeteners such as aspartame, aspartic acid, acesulfame, and stevioside.

Claims (7)

1. A method for pharmacologically inducing the fed mode in a subject, said subject being a human or a dog weighing at least 5 kg, said method comprising administering to said subject a fed mode inducing agent selected from the group consisting of

alkali and alkaline earth metal docusates,

said administration being in an amount and a manner that causes release of the fed mode inducing agent in the stomach and retention of the fed mode inducing agent in the stomach so as to cause onset of the fed mode in said subject.

2. A method in accordance with claim 1 in which said fed mode inducing agent is a member selected from the group consisting of calcium docusate and sodium docusate.

3. A method in accordance with claim 1 in which said fed mode inducing agent is sodium docusate.

4. A method in accordance with claim 1 in which the amount of said fed mode inducing agent is from about 30 mg to about 1000 mg.

5. A method in accordance with claim 1 in which the amount of said fed mode inducing agent is from about 60 mg to about 400 mg.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Feb 13, 2020
From: DEERFIELD PRIVATE DESIGN FUND III, L.P., AS COLLATERAL AGENT
To: ASSERTIO THERAPEUTICS, INC. (F/K/A DEPOMED, INC.)
Reel/Frame 051930/0778 →
CORRECTIVE ASSIGNMENT TO CORRECT THE APPLICATION NUMBERS 09402976, 10196590, 11562002,11562173,12047388,13078575,13541314,13541325, 14747289 PREVIOUSLY RECORDED ON REEL 047322 FRAME 0843. ASSIGNOR(S) HEREBY CONFIRMS THE MERGER. Recorded May 7, 2019
From: DEPOMED, INC.
To: ASSERTIO THERAPEUTICS, INC.
Reel/Frame 049110/0550 →
MERGER Recorded Sep 11, 2018
From: DEPOMED, INC.
To: ASSERTIO THERAPEUTICS, INC.
Reel/Frame 047322/0843 →
SECURITY INTEREST Recorded Apr 2, 2015
From: DEPOMED, INC.
To: DEERFIELD PRIVATE DESIGN FUND III, L.P.
Reel/Frame 035355/0039 →